BioMarin Pharmaceutical (BMRN)
Health Care · Rare Disease Biotechnology · NASDAQ
BioMarin is a biotechnology leader dedicated to transforming the lives of patients with rare, genetically defined diseases through innovative, category-defining medicines.
What BioMarin Pharmaceutical does
BioMarin Pharmaceutical is a global biotechnology company focused on developing and commercializing therapies for rare, genetically defined diseases. The company maintains a portfolio of commercial products addressing metabolic conditions, achondroplasia, phenylketonuria, and other genetic disorders, recently expanded by the acquisition of Amicus Therapeutics. It utilizes advanced genetic science and drug discovery approaches to target serious, life-threatening conditions.
Themes: rare diseases, genetic medicine, metabolic disorders, biotechnology innovation, specialty pharmaceuticals
Fundamentals
- Price$66.70 as of 2026-08-21 close
- Market cap$12.9B as of 2026-08-21
- 1-year return+14.9% 2025-08-21 close $58.07 → 2026-08-21 close $66.70
- P/E182.98 as of 2026-08-24
- Net margin+2.1% as of 2026-08-24
- Gross margin+79.6% as of 2026-08-24
- ROE+1.2% as of 2026-08-24
- Debt / equity0.66 as of 2026-08-24
- Revenue growth (YoY)+11.2% as of 2026-08-24
- Revenue CAGR (3y)+15.4% SEC XBRL
- Beta0.21 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How BMRN compares in its sector
- price-to-earnings ratiotop 10% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BMRN is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
61.1 #156 of 1,704 scored · #39 of 240 in Health Care
Momentum 68th: MACD momentum is positive; trend 66th: a strong uptrend, with buyers in control; weakest is setup 45th: day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How BioMarin Pharmaceutical looks technically
BioMarin Pharmaceutical (BMRN) is trading 16.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 21 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 8 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 16.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +16.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $60.64 | $60.64 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $57.18 | $57.18 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 63.05. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 21 trading days ago — a "golden cross", a bullish long-term signal | 21 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 31.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 58.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($58.89 to $70.98) — its "stochastic" reading is 65 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 64.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $70.98 | $70.98 |
|---|---|---|
| From the 52-week high | it is 6.0% below its 52-week high (its highest price of the past year) | -6.0% |
| Above the 52-week low | it is 35.4% above its 52-week low (its lowest price of the past year) | +35.4% |
| Below the 52-week high | it is 6.0% below its highest point of the past year | 6.0% |
| Since a 20-day breakout | it made a new 20-day high about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day high about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $151.75 (set on 2015-07-20) | $151.75 |
| Given back of the 52-week move | over the past year its closes ranged ($49.67 to $70.24), and it has given back roughly a quarter of its rise from last year’s low — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $56.87 to $57.53. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.2% |
| From the all-time high | it is 56.0% below its all-time high | -56.0% |
| Nearest price level | it is trading 1.5% above a support level at $65.67 — a price it turned at three times since 2024-10-31, most recently on 2026-02-24. Since 2024-08-21 it has 10 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.5% |
| All-time low | its lowest closing price on record is $6.94 (set on 2005-10-12) | $6.94 |
| Above the all-time low | it is 861.1% above its all-time low | +861.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.98 between its high and its low — about 3.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.98 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $57.05 and $72.16 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $57.05 – $64.61 – $72.16 |
| Typical daily range (% of price) | its price moves about 3.0% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.0% |
| Stretch from the 200-day average | it is trading 4.8 daily ranges above its 200-day average price (16.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.79× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.2% since the prior reading | +1.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 5.2% above the previous close 10 sessions ago and has not traded back through the level it left behind at 61.46 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.2% |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -3.79% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 10.3 percentage points (the stock gained 12.6% while the market gained 2.3%) | +10.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 20.2 percentage points (the stock gained 23.3% while the market gained 3.1%) | +20.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 7.0 percentage points (the stock gained 4.1% while the market gained 11.1%) | -7.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 5.6 percentage points (the stock gained 14.9% while the market gained 20.5%) | -5.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 14% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.0% of the share price. | +14.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $58.12 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +14.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $67.12 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -0.6% |
Price levels it has turned at before
BMRN last closed at $66.70 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $65.67 | Support | 1.5% below the last close | turned there three times · 2024-10-31 to 2026-02-24 |
| $67.93 | Resistance | 1.9% above the last close | turned there six times · 2024-09-24 to 2025-03-14 |
| $63.93 | Support | 4.2% below the last close | turned there three times · 2024-12-19 to 2025-12-19 |
| $62.44 | Support | 6.4% below the last close | turned there four times · 2024-12-04 to 2026-07-28 |
| $71.04 | Resistance | 6.5% above the last close | turned there three times · 2024-09-30 to 2026-08-12 |
| $73.34 | Resistance | 10.0% above the last close | turned there twice · 2025-03-07 to 2025-03-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $63.05.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $64.94 and $68.13 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $70.98.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · lagging the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.72 mean, 1=Strong Buy…5=Strong Sell) — 25 analysts
- Mean price target$90.56 range $60.00 – $124.00; median $86.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BMRN
- Consensus EPS estimate$1.37 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Potential for failure or delays in clinical development and regulatory approval processes for pipeline candidates.","Dependence on a limited number of commercial products for the majority of revenue.","Exposure to macroeconomic risks including inflation, geopolitical instability, and regulatory changes."]
What changed in the latest 10-Q
AI-assisted comparison of BMRN's 10-Q filed 2026-05-05 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- ROCTAVIAN footnote added noting 2026 announcement that company will no longer market the product (filed 2026-05-05)
- April 2026 Amicus Therapeutics acquisition announcement for $14.50/share ($4.8 billion equity value) with $433.0 million debt repayment (filed 2026-05-05)
- Amicus acquisition details including GALAFOLD, POMBILITI, OPFOLDA, and DMN-200 in Phase 3 for FSGS (filed 2026-05-05)
- April 2026 senior secured term loan facilities of $2.8 billion and $600.0 million revolving credit facility announcement (filed 2026-05-05)
- February 2026 issuance of $850.0 million 5.5% senior unsecured notes due 2034 (filed 2026-05-05)
- Description of macroeconomic risks expanded to include 'wars and military conflicts' (filed 2026-05-05)
- Added language about periodic strategic portfolio assessment potentially discontinuing programs (filed 2026-05-05)
- Removed:
- Reference to 'eight commercial therapies' changed to portfolio listing without specific count (filed 2025-10-28)
- Reference to nine months ended and comparative year-to-date financial data removed from Financial Highlights (filed 2025-10-28)
- Specific Q3 2025 financial data (Q3 2024 comparison, nine months data) removed (filed 2025-10-28)
- October 2025 ROCTAVIAN divestment plan announcement removed (filed 2025-10-28)
- September 2025 ASBMR meeting VOXZOGO spinal morphology data announcement removed (filed 2025-10-28)
- September 2025 PALYNZIQ Phase 3 PEGASUS study data announcement removed (filed 2025-10-28)
- August 2025 BMN 333 Phase 1 data announcement removed (filed 2025-10-28)
- July 2025 Inozyme Pharma acquisition announcement removed (filed 2025-10-28)
- Reworded:
- Report period changed from September 30, 2025 to March 31, 2026 (filed 2026-05-05 vs 2025-10-28)
- Year context changed from '2025' to '2026' in multiple places (filed 2026-05-05)
- Financial comparison changed from three months ended September 30 2025 vs 2024 to March 31 2026 vs 2025 (filed 2026-05-05)
- Overview reference to 'during 2025' changed to 'during 2026' (filed 2026-05-05)
- Notes:
- The older filing (2025-10-28) appears to be for Q3 2025 (nine months ended September 30, 2025) while newer filing (2026-05-05) is for Q1 2026 (three months ended March 31, 2026), making these different reporting periods
- Financial Highlights table structure differs between filings due to different quarterly vs YTD reporting periods
- Text appears truncated in newer filing at end of debt facility disclosure
Risk Factors
- Added:
- Reference to Form 10-K for year ended December 31, 2025 (filed February 26, 2026) in newer filing (2026-05-05)
- Statement that company 'continues to pursue' corporate strategy announced in 2024 (newer filing)
- Addition of Amicus Acquisition in April 2026 to expand and diversify rare disease product portfolio (newer filing)
- Statement about 'expanding our pipeline through external innovation' (newer filing)
- Removal of Turner syndrome and SHOX deficiency from VOXZOGO expansion indications (newer filing removes these)
- Change from 'announced that we are advancing' to 'continuing to advance' VOXZOGO (newer filing)
- Removed:
- Reference to Form 10-K for year ended December 31, 2024 (filed February 24, 2025) removed in newer filing
- Turner syndrome removed from list of VOXZOGO expansion indications (older filing included it)
- SHOX deficiency removed from list of VOXZOGO expansion indications (older filing included it)
- Phrase 'we have announced that we are advancing' changed to 'we are continuing to advance' (wording change noted)
- Reworded:
- Acquisitions section: older text states 'we have acquired, and we may continue to acquire' changed to 'we have acquired, entered into agreements to acquire, and may continue to acquire' in newer filing
- Acquisitions section: 'For example, in July 2025, we completed the acquisition of Inozyme' changed to 'For example, in April 2026, we acquired Amicus... In addition, in July 2025, we completed the acquisition of Inozyme' in newer filing
- Wording about licensing: 'We have in the past attempted and may in the future attempt to license' changed to 'We have in the past attempted and may in the future attempt to license' (older text stated 'We will attempt' which is softer in newer text)
- Reference to BMN 401 indications: 'currently being assessed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency' in older changed to 'currently being assessed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency' with capitalization change in newer
- Notes:
- Both filings marked certain risk factors with asterisks indicating substantive changes; new filing specifically notes Amicus Acquisition (April 2026) not present in older filing dated October 2025
- Indications for VOXZOGO were narrowed between filings; Turner syndrome and SHOX deficiency removed
- Text appears truncated in both versions at end of acquisitions section, preventing full comparison of remaining content
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 1 sell ($176682) — 1 selling insider
Most recent open-market transaction: 2026-05-07. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BMRN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
7 institutional 13F filers reported holding BMRN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 43,672,104
- Reported value $2,467,037,103
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BMRN had 12,504,131 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BMRN had 6.46% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.42 days to cover at the same settlement.
- Reported short interest (shares) 12,504,131
- Short interest (% of shares outstanding) 6.46%
- Prior settlement (shares) 14,315,984
- Reported change -12.66%
- Days to cover (reported) 7.42
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sanofi (SNY)
- Takeda Pharmaceutical (TAK)
- Ultragenyx Pharmaceutical (RARE)
- Sarepta Therapeutics (SRPT)
- Alnylam Pharmaceuticals (ALNY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BMRN vs…
BioMarin Pharmaceutical is found in…
Frequently asked questions
What does BioMarin Pharmaceutical (BMRN) do?
BioMarin Pharmaceutical is a global biotechnology company focused on developing and commercializing therapies for rare, genetically defined diseases. The company maintains a portfolio of commercial products addressing metabolic conditions, achondroplasia, phenylketonuria, and other genetic disorders, recently expanded by the acquisition of Amicus Therapeutics. It utilizes advanced genetic science and drug discovery approaches to target serious, life-threatening conditions.
What sector is BioMarin Pharmaceutical (BMRN) in?
BioMarin Pharmaceutical (BMRN) is classified in the Health Care sector. Its industry is Rare Disease Biotechnology. It trades on NASDAQ.
Who are BioMarin Pharmaceutical's (BMRN) competitors?
Notable peers of BioMarin Pharmaceutical (BMRN) include Sanofi, Takeda Pharmaceutical, Ultragenyx Pharmaceutical, Sarepta Therapeutics and Alnylam Pharmaceuticals. This peer set is informational only — not financial advice.
Is BioMarin Pharmaceutical (BMRN) overbought or oversold right now?
BioMarin Pharmaceutical (BMRN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BMRN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.